Free
Meeting Abstracts  |   July 2006
Effects of Bupivacaine and Tetrodotoxin on Carrageenan-induced Hind Paw Inflammation in Rats (Part 2): Cytokines and p38 Mitogen-activated Protein Kinases in Dorsal Root Ganglia and Spinal Cord
Author Affiliations & Notes
  • Hélène Beloeil, M.D., Ph.D.
    *
  • Ru-Rong Ji, Ph.D.
  • Charles B. Berde, M.D, Ph.D.
  • * Research Fellow, Department of Anesthesiology, Children’s Hospital and Harvard Medical School, Boston, Massachusetts. † Assistant Professor, Pain Research Center, Department of Anesthesiology, Brigham & Women’s Hospital and Harvard Medical School, Boston, Massachusetts. ‡ Professor, Department of Anesthesiology, Perioperative and Pain Medicine, Children’s Hospital and Harvard Medical School, Boston, Massachusetts.
Article Information
Meeting Abstracts   |   July 2006
Effects of Bupivacaine and Tetrodotoxin on Carrageenan-induced Hind Paw Inflammation in Rats (Part 2): Cytokines and p38 Mitogen-activated Protein Kinases in Dorsal Root Ganglia and Spinal Cord
Anesthesiology 7 2006, Vol.105, 139-145. doi:
Anesthesiology 7 2006, Vol.105, 139-145. doi:
LOCAL anesthetics (LAs) can inhibit components of the inflammatory response.1 We reported that bupivacaine and tetrodotoxin via  a contralateral or ipsilateral block could attenuate the inflammatory hind paw edema and hyperalgesia induced by hind paw injection of carrageenan in rats.2 Systemic administration of either bupivacaine or tetrodotoxin was ineffective in preventing hind paw edema and hyperalgesia. Bupivacaine by all three routes inhibited lipopolysaccharide-stimulated production of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) in cultures of circulating leukocytes and partially inhibited Staphylococcus aureus  Cowan (SAC)–stimulated production of TNF-α, but it did not inhibit production of interleukin 10 (IL-10). Tetrodotoxin by all three routes had no effect on stimulated production of cytokines in cultures of circulating leukocytes.2 The mechanisms underlying contralateral effects of sciatic blockade remain unexplained.
Several lines of evidence suggest that peripheral inflammation elicits central changes in proinflammatory cytokines that mediate the cascade underlying hyperalgesia and allodynia.3 For example, up-regulation of spinal IL-1β expression seems to parallel the development and maintenance of formalin-induced mechanical allodynia.4 The mitogen-activated protein kinases (MAPKs) are a family of signaling molecules that transduce extracellular stimuli into intracellular responses in a wide variety of circumstances. The MAPK family includes extracellular signal–regulated kinases, p38, and c-Jun N-terminal kinase.5 p38 has been implicated in exaggerated pain states.6 p38 is activated in dorsal root ganglion (DRG) nociceptor neurons by peripheral inflammation and participates in the maintenance of inflammatory heat hyperalgesia.7 Carrageenan-induced inflammation also triggers phosphorylation of spinal p38 MAPK.8 p38 MAPK plays a dual role in the generation of, and cellular response to, certain cytokines. It has a recognized role in TNF-α and IL-1β production.9 A sequential role for TNF-α and p38 in the induction of neuropathic pain was shown in a spinal nerve ligation model.8 
A variety of analgesics not commonly regarded as antiinflammatory agents may act in part by influencing cytokine production. For example, perineural administration of clonidine reduced both hyperalgesia and local cytokine production in a model of nerve injury.10 LA modulation of inflammatory responses could be a result of an action on MAPK pathways at a spinal cord and DRG level. To explore further action of LAs, we examined the effect of bupivacaine or tetrodotoxin sciatic block (ipsilateral or contralateral to the side of hind paw inflammation) on the content of major proinflammatory cytokines (TNF-α and IL-1β) and p38 and phosphorylated p38 (p-p38) MAPK in the ipsilateral and contralateral DRGs and the ipsilateral and contralateral sides of the spinal dorsal horn after carrageenan-induced paw inflammation. Because our previous results showed similar effects of tetrodotoxin and bupivacaine sciatic blocks on local hyperalgesia and hind paw inflammation but different effects of the two drugs on systemic cytokine production, we included tetrodotoxin groups in the current study. Unlike conventional amino-amide and amino-ester LAs, the site 1 sodium channel–blocking toxin tetrodotoxin seems to act specifically on sodium channels.11 
Materials and Methods
All procedures were conducted in accordance with the Children’s Hospital Animal Care and Use Committee (Boston, Massachusetts). Young adult male Sprague-Dawley rats weighing 250–300 g were used. The animals were kept on a 12-h light–dark cycle with free access to food and water. The rats were handled repeatedly over at least 3 days before experiments to habituate them to the investigators and the testing paradigm.
Solutions
Carrageenan was prepared fresh before each experiment (0.2 ml of 2% solution of lambda carrageenan in saline). Tetrodotoxin (50 μm)12 stock solutions were made by dissolving 1 mg tetrodotoxin (Sigma Chemical Co., St. Louis, MO) in 10 ml of 20 mm citrate buffer. Bupivacaine, 0.5% (Sigma Chemical), with epinephrine was used as the LA. Epinephrine from a commercial 1:1,000 (1 mg/ml) solution (American Regent Laboratories, Shirley, NY) was diluted to 55 μm (1:100,000) final concentration and prepared fresh for each set of injections.
Sciatic Blockade Technique
Before nerve block injections, rats were anesthetized briefly with isoflurane (2–4% inspired concentration in 100% oxygen) by facemask. The block was initiated by introducing a 23-gauge needle posteromedially to the greater trochanter, pointed in an anteromedial direction. When bone was touched, the needle was withdrawn 1 mm and the drug was injected. To provide a prolonged effect, bupivacaine and tetrodotoxin were injected with 1:100,000 epinephrine, and reinjections were performed 6 h later. This paradigm was chosen in preference to a previous approach using sustained release of LAs from biodegradable microspheres, because previous work showed that the microspheres induced inflammation, and the coincorporated dexamethasone could produce confounding local and systemic antiinflammatory effects.13 The final volume of injectate was 0.2 ml test solution. The left leg was always used for blocks.
Experimental Groups
Animals were assigned to 1 of 10 experimental groups (table 1). Each animal received two types of injections: a left sciatic block (with bupivacaine plus epinephrine, tetrodotoxin plus epinephrine, or saline plus epinephrine) and a subcutaneous paw injection (with either carrageenan or saline). The animals in the ipsilateral sciatic block groups received their hind paw injections (with either carrageenan or saline) on the left, whereas animals in the contralateral block groups received hind paw injections on the right. The animals in the forepaw injection groups received a right subcutaneous forepaw injection (with either carrageenan or saline) and a left sciatic block (with saline plus epinephrine). The animals received a second left perisciatic injection 6 h later to provide a prolonged effect of bupivacaine, tetrodotoxin, or saline.
Table 1. Summary of the Treatment Groups 
Image not available
Table 1. Summary of the Treatment Groups 
×
Tissue Preparation and Assessment of TNF-α, IL-1β, p38, and Phosphorylated p38 in the DRGs and Spinal Cord
Animals were deeply anesthetized with pentobarbital and then killed by decapitation 15 h after the hind paw or forepaw injection. Ipsilateral and contralateral L4, L5 DRGs and the corresponding right and left ventral and dorsal quadrants of the spinal cord were removed. The wet weight of each sample was determined, and the tissues were frozen at −80°C. Each sample was homogenized in an ice bath with a lysis buffer containing proteinase inhibitors and phosphatase inhibitors, with the following composition: 1 mm EDTA, 0.5% (wt/vol) Triton X-100, 5 mm sodium fluoride, 6 m urea, 10 μg/ml leupeptin, 1 μg/ml pepstatin, 100 μm phenylmethanesulfonyl fluoride, 3 μg/ml aprotinin, 2.5 mm sodium pyrophosphate, and 1 mm sodium orthovanadate in phosphate-buffered saline14 (Roche Boehringer, Mannheim, Germany) using an ultrasound sonicator. The homogenates were centrifuged (15,000g  ) for 30 min at 4°C, and the supernatants were aliquoted and stored at −80°C. Concentrations of TNF-α, IL-1β, p38 MAPK, and p-p38 MAPK were measured with commercially available sandwich enzyme-linked immunosorbent assays (DuoSet; R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions.
Statistical Analysis
The distribution of cytokines and MAPK concentrations in each unit were checked for normality using the Shapiro-Wilk test. The difference between groups was assessed using a one-way analysis of variance with post hoc  analysis via  Fisher protected least significant difference test. Data are presented in figures as mean ± SD. A P  value below 0.05 was considered as the minimum level of statistical significance.
Results
TNF-α in Spinal Cord and DRGs (n = 4 or 5/Group)
A significant increase in TNF-α content in ipsilateral and contralateral dorsal spinal cord (fig. 1A) and bilateral DRGs (fig. 1B) was observed at 15 h in the hind paw carrageenan group (right hind paw carrageenan plus left perisciatic saline) compared with the control group (right hind paw saline plus left perisciatic saline). In the groups receiving bupivacaine or tetrodotoxin sciatic blocks with hind paw saline (right hind paw saline plus left perisciatic bupivacaine or tetrodotoxin block), TNF-α content in ipsilateral and contralateral dorsal spinal cord (fig. 1A) and bilateral DRGs (fig. 1B) was not significantly different from that observed in the corresponding sites in the control group. In the groups receiving hind paw carrageenan and either an ipsilateral or a contralateral sciatic block with either bupivacaine or tetrodotoxin, TNF-α content was significantly higher in bilateral spinal cord and bilateral DRGs than that observed in the control group but not significantly different from corresponding sites in the hind paw carrageenan group.
Fig. 1. Tumor necrosis factor-α content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
Fig. 1. Tumor necrosis factor-α content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
	*P  < 0.05. 
Fig. 1. Tumor necrosis factor-α content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
×
IL-1β in Spinal Cord and DRGs (n = 4 or 5/Group)
A significant increase in IL-1β content was observed in ipsilateral and contralateral dorsal spinal cord (fig. 2A) and in bilateral DRGs (fig. 2B) at 15 h in the hind paw carrageenan group compared with the control group. In the groups receiving hind paw saline along with sciatic blocks with either bupivacaine or tetrodotoxin, IL-1β content in either ipsilateral or contralateral dorsal spinal cord (fig. 2A) or bilateral DRGs (fig. 2B) was not significantly different from that observed in the corresponding sites in the control group. In the groups receiving hind paw carrageenan and either ipsilateral or contralateral sciatic blocks with either bupivacaine or tetrodotoxin, IL-1β levels were significantly higher in bilateral spinal cord and DRGs than those observed in the corresponding sites in the control group but not significantly different from the corresponding sites in the carrageenan group.
Fig. 2. Interleukin-1β content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
Fig. 2. Interleukin-1β content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
	*P  < 0.05. 
Fig. 2. Interleukin-1β content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
×
p38 and p-p38 MAPK in Spinal Cord and DRGs (n = 3–5/Group)
Total p38 (nonphosphorylated and phosphorylated) content was not increased at 15 h in the hind paw carrageenan groups compared with the control groups in either ipsilateral or contralateral dorsal spinal cord (fig. 3A) or in bilateral DRGs (fig. 3B). Phosphorylated p38 content did not increase in the spinal cord in the hind paw carrageenan group (fig. 4A) compared with control, but it did increase significantly in bilateral DRGs (fig. 4B). In the groups receiving hind paw carrageenan and an ipsilateral or contralateral block with either bupivacaine or tetrodotoxin, p-p38 content in bilateral DRGs was significantly greater than at corresponding sites for the control group but not significantly different from that at corresponding sites in the hind paw carrageenan group (fig. 4B).
Fig. 3. p38 content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
Fig. 3. p38 content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
Fig. 3. p38 content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
×
Fig. 4. Phosphorylated p38 (p-p38) content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
Fig. 4. Phosphorylated p38 (p-p38) content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
	*P  < 0.05. 
Fig. 4. Phosphorylated p38 (p-p38) content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
×
Effects of Carrageenan Injections in the Forepaw
Because of the remarkable finding of increased content of cytokines and p-p38 MAPK in contralateral lumbar DRGs after hind paw carrageenan injection, an additional control experiment was added with groups receiving forepaw carrageenan injections, to evaluate the possibility that activation of cytokines and p-p38 MAPK in lumbar DRGs on the side contralateral to hind paw injection might reflect a systemic, rather than segmental, inflammatory response. Animals receiving carrageenan injections in a forepaw did not evoke any increases in production of either TNF-α (fig. 1), IL-1β (fig. 2), p38 MAPK (fig. 3), or p-p38 MAPK (fig. 4) in either lumbar spinal cord (part A of each figure) or bilateral L4–L5 DRGs (part B of each figure).
Discussion
In the current study, we examined two primary hypotheses: (1) that carrageenan-induced hind paw inflammation could activate inflammatory pathways ipsilaterally and/or contralaterally in both spinal cord and DRGs and (2) that sciatic blockade with either bupivacaine or tetrodotoxin could inhibit these inflammatory responses. TNF-α and IL-1β content showed bilateral significant increases in the dorsal spinal cord and lumbar DRGs after a unilateral hind paw challenge with carrageenan. In parallel, p-p38 MAPK content was bilaterally increased in the lumbar DRGs after unilateral hind paw carrageenan injection, although not in spinal cord. Total p38 (nonphosphorylated and phosphorylated) content was not increased in the carrageenan groups, compared with the control groups, either in spinal cord or in DRGs. This suggested that the increase in p-p38 in bilateral lumbar DRGs may reflect increased phosphorylation rather than increased substrate. Neither ipsilateral nor contralateral sciatic blockade with bupivacaine or tetrodotoxin had any effect on the evoked production of the two cytokines or p-p38 MAPK.
Activation of TNF-α, IL-1β, and p-p38 MAPK in contralateral DRGs was a remarkable observation, because somatic afferent peripheral fibers project to ipsilateral DRGs and are not thought to have contralateral connections at the level of DRGs. Ji et al.  7 reported similar activation of p-p38 MAK in bilateral DRGs, but not in spinal cord, after Freund complete adjuvant hind paw injections. A trivial cause for this contralateral DRG activation could have been due to a systemic, rather than a regional or segmental, mechanism. To test this possibility, additional groups of animals received carrageenan injections into a forepaw. Forepaw injections did not increase TNF-α, IL-1β, or p-p38 MAPK content in lumbar spinal dorsal horn or lumbar DRGs. This latter observation supports the view that hind paw carrageenan-induced activation of cytokines and p-p38 MAPK in bilateral lumbar DRGs involves a regional or segmental, rather than systemic, mechanism.
Bilateral, segmental activation of inflammatory mechanisms in DRGs after a unilateral injury or inflammatory stimulus may be relevant to mirror-image syndromes noted in some patients with chronic pain. Patients with complex regional pain syndromes not infrequently develop bilateral pain and neurovascular signs and symptoms after a unilateral injury.15 Oaklander et al.  16–18 have provided evidence that unilateral nerve injury produces contralateral distal sensory loss and bilateral down-regulation of messenger RNA encoding the SCN10-A sodium channel in DRGs in rats, and contralateral neurite loss in the skin was observed in patients with unilateral postherpetic neuralgia. As noted by Oaklander, these findings are remarkable because “There are no known anatomical connections between neurons that innervate homologous right and left body parts.”18 The mechanisms underlying contralateral activation of cytokines and kinases in DRGs, contralateral down-regulation of sodium channels, and contralateral cutaneous neurite loss merit further study and may be relevant to clinical mirror-image syndromes. Contralateral mirror-image pain syndromes and contralateral-directed treatments for phantom limb pain and complex regional pain syndromes may involve a complex interplay of supraspinal, spinal, and peripheral mechanisms.19–26 
Previous studies, using a variety of inflammatory substances, including carrageenan, formalin, zymosan, or Freund complete adjuvant, have shown that peripheral inflammation is associated with activation in spinal astrocytes and microglia and increased concentrations of cytokines, MAPK, or both in either spinal cord or DRGs.4,6–8,27,28 Pharmacologic interventions to block actions of IL-1β or TNF-α, or blockade of p38 MAPK phosphorylation can diminish either inflammatory edema or hyperalgesia in these models.27,29,30 Cytokines may act directly on neurons via  their receptors or indirectly by stimulating the local release of arachidonic acid, cyclooxygenase products, and nitric oxide.31,32 Peripheral hind paw inflammation can activate cytokines both spinally and supraspinally33 and can also activate descending modulatory systems from the locus coeruleus and the nucleus subcoeruleus bilaterally.34 Roles of the MAPK family, especially p-38, have been examined in several different pain models.7,8,28,35 Injection of formalin into the paw induces p38 activation in bilateral DRGs.28 Peripheral inflammation and nerve injury induce p38 MAPK activation in DRGs, and the corresponding nociceptive behaviors are prevented by p38 MAPK inhibition.7,8 Moreover, p38 MAPK is known to regulate the synthesis of cytokines, cyclooxygenase 2, and inducible nitric oxide synthase.36 Other members of the MAPK family, including extracellular signal–regulated protein kinases, are also implicated in pain signaling.37–41 
Previous studies of effects of LAs on inflammatory hyperalgesia and local, systemic, and spinal inflammatory markers have produced conflicting results42–50 and have involved a variety of different models, assays, and methods of LA administration. In our companion study,2 as in other studies,42,43 the local inflammatory edema and hyperalgesia induced by carrageenan was inhibited by a bupivacaine sciatic block. LA actions on spinal inflammation seem complex and may reflect differential effects on microglia versus  astroglia.46 
Contralateral intramuscular injection of bupivacaine microspheres in mice inhibited carrageenan-evoked increases in stimulated production of cytokines in circulating blood cell cultures.45 Previous studies by Bileviciute-Ljungar et al.  44,49,50 using both inflammatory and nerve injury models found antihyperalgesic effects of either bupivacaine or lidocaine administered in several different locations in the limb contralateral to the site of injury. In addition, these investigators reported that contralateral lidocaine administration inhibited activity in wide-dynamic-range dorsal horn neurons on the side ipsilateral to a chronic constriction injury.49 They suggested the possible involvement of crossed spinal reflexes.
We attempted to avoid some of the confounding factors in previous studies and to elucidate local, contralateral, systemic, and spinal mechanisms of LAs on inflammatory responses by using ipsilateral and contralateral sciatic blocks and remote systemic injections of either bupivacaine or tetrodotoxin in combination with epinephrine, with repeat injections 6 h later. This approach permits dense sensory and motor blockade over the 15-h period required to permit evolution of inflammatory edema and hyperalgesia in the carrageenan model.
Because this method of prolonged sciatic blockade, using either bupivacaine or tetrodotoxin, was able to suppress local hind paw edema and hyperalgesia in the first part of this two-part study,2 and because either perisciatic or systemic bupivacaine was able to suppress a systemic inflammatory marker, namely evoked cytokine production in whole blood cultures, it was somewhat surprising that neither bupivacaine nor tetrodotoxin suppressed any aspect of spinal cytokine or MAPK activation in the current study. Future studies may examine higher doses of bupivacaine or tetrodotoxin, to achieve even more intense degrees of blockade, concomitant saphenous nerve blockade, or other interventions.
In conclusion, this two-part investigation showed that actions of LAs on inflammation are complex and reflect interplay of local, contralateral, systemic, and spinal mechanisms. Neither bupivacaine nor tetrodotoxin by any route was effective in blunting increases in cytokines or p-p38 MAPK in spinal cord or DRGs. Future animal studies and clinical intervention studies will need to consider multiple sites and mechanisms of LA action that can influence success or failure in the treatment of acute or chronic pain.
Jennifer Jaskiewicz and Michelle Stein (Research Assistants, Department of Anesthesiology, Perioperative and Pain Medicine, Children’s Hospital, Boston, Massachusetts) provided excellent technical assistance with preparation of the figures. The authors would like to thank Dan Benhamou and Jean-Xavier Mazoit (Professors, Hopital de Bicetre, Paris, France) for their encouragement and support of this work, which is a portion of Dr. Beloeil’s Ph.D. thesis at the University of Paris.
References
Hollmann MW, Durieux ME: Local anesthetics and the inflammatory response: A new therapeutic indication? Anesthesiology 2000; 93:858–75Hollmann, MW Durieux, ME
Beloeil H, Ababneh Z, Chung R, Zurakowski D, Mulkern RV, Berde CB: Effects of bupivacaine and tetrodotoxin on carrageenan-induced hind paw inflammation in rats (part 1). Hyperalgesia, edema, and systemic cytokines. Anesthesiology 2006; 105:128–38Beloeil, H Ababneh, Z Chung, R Zurakowski, D Mulkern, RV Berde, CB
Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF: Characterization of cytokine-induced hyperalgesia. Brain Res 1994; 654:15–26Watkins, LR Wiertelak, EP Goehler, LE Smith, KP Martin, D Maier, SF
Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA: Acute peripheral inflammation induces moderate glial activation and spinal IL-1b expression that correlates with pain behavior in the rat. Brain Res 1999; 829:209–21Sweitzer, SM Colburn, RW Rutkowski, M DeLeo, JA
Obata T, Brown G, Yaffe M: Mapkinase pathways activated by stress: The p38 Mapk pathway. Crit Care Med 2000; 28 (suppl):N67–77Obata, T Brown, G Yaffe, M
Watkins LR, Milligan ED, Maier SF: Spinal cord glia: New player in pain. Pain 2001; 93:201–5Watkins, LR Milligan, ED Maier, SF
Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36:57–68Ji, RR Samad, TA Jin, SX Schmoll, R Woolf, CJ
Schafers M, Svensson CI, Sommer C, Sorkin LS: Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003; 23:2517–21Schafers, M Svensson, CI Sommer, C Sorkin, LS
Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:739–46Lee, JC Laydon, JT McDonnell, PC Gallagher, TF Kumar, S Green, D McNulty, D Blumenthal, MJ Heys, JR Landvatter, SW Strickler, JE McLaughlin, MM Siemens, IR Fisher, SM Livi, GP White, JR Adams, JL Young, PR
Lavand’homme PM, Eisenach JC: Perioperative administration of the alpha2-adrenoceptor agonist clonidine at the site of nerve injury reduces the development of mechanical hypersensitivity and modulates local cytokine expression. Pain 2003; 105:247–54Lavand’homme, PM Eisenach, JC
Ritchie JM, Rogart RB: The binding of saxitoxin and tetrodotoxin to excitable tissue. Rev Physiol Biochem Pharmacol 1977; 79:1–50Ritchie, JM Rogart, RB
Kohane DS, Yieh J, Lu NT, Langer R, Strichartz GR, Berde CB: A re-examination of tetrodotoxin for prolonged duration local anesthesia. Anesthesiology 1998; 89:119–31Kohane, DS Yieh, J Lu, NT Langer, R Strichartz, GR Berde, CB
Kohane DS, Smith SE, Louis DN, Colombo G, Ghoroghchian P, Hunfeld NGM, Berde CB, Langer R: Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain 2003; 104:415–21Kohane, DS Smith, SE Louis, DN Colombo, G Ghoroghchian, P Hunfeld, NGM Berde, CB Langer, R
Sweitzer S, Martin D, DeLeo JA: Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001; 103:529–39Sweitzer, S Martin, D DeLeo, JA
Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, Sullivan P, Meier P, Zurakowski D, Masek BJ, Berde CB: Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr 2002; 141:135–40Lee, BH Scharff, L Sethna, NF McCarthy, CF Scott-Sutherland, J Shea, AM Sullivan, P Meier, P Zurakowski, D Masek, BJ Berde, CB
Oaklander AL, Belzberg AJ: Unilateral nerve injury down-regulates mRNA for Na+ channel SCN10A bilaterally in rat dorsal root ganglia. Brain Res Mol Brain Res 1997; 52:162–5Oaklander, AL Belzberg, AJ
Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA: Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol 1998; 44:789–95Oaklander, AL Romans, K Horasek, S Stocks, A Hauer, P Meyer, RA
Oaklander A, Brown J: Unilateral nerve injury produces bilateral loss of distal innervation. Ann Neurol 2004; 55:639–44Oaklander, A Brown, J
Milligan ED, Twining C, Chacur M, Biedenkapp J, O’Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003; 23:1026–40Milligan, ED Twining, C Chacur, M Biedenkapp, J O’Connor, K Poole, S Tracey, K Martin, D Maier, SF Watkins, LR
McCabe CS, Haigh RC, Shenker NG, Lewis J, Blake DR: Phantoms in rheumatology. Novartis Found Symp 2004; 260:154–74McCabe, CS Haigh, RC Shenker, NG Lewis, J Blake, DR
Moseley GL: Graded motor imagery is effective for long-standing complex regional pain syndrome: A randomised controlled trial. Pain 2004; 108:192–8Moseley, GL
McCabe CS, Haigh RC, Halligan PW, Blake DR: Simulating sensory-motor incongruence in healthy volunteers: Implications for a cortical model of pain. Rheumatology 2005; 44:509–16McCabe, CS Haigh, RC Halligan, PW Blake, DR
Ramachandran VS, Rogers-Ramachandran D: Synaesthesia in phantom limbs induced with mirrors. Proc Biol Sci 1996; 263:377–86Ramachandran, VS Rogers-Ramachandran, D
Gross D: Contralateral local anaesthesia in the treatment of phantom limb and stump pain. Pain 1982; 13:313–20Gross, D
Birbaumer N, Lutzenberger W, Montoya P, Larbig W, Klaus Unertl K, Töpfner S, Grodd W, Edward Taub E, Flor H: Effects of regional anesthesia on phantom limb pain are mirrored in changes in cortical reorganization. J Neurosci 1997; 5503–8Birbaumer, N Lutzenberger, W Montoya, P Larbig, W Klaus Unertl, K Töpfner, S Grodd, W Edward Taub, E Flor, H
Carabelli RA, Kellerman WC: Phantom limb pain: Relief by application of TENS to contralateral extremity. Arch Phys Med Rehabil 1985; 66:466–7Carabelli, RA Kellerman, WC
Rothwell NJ, Hopkins SJ: Cytokines and the nervous system: II. Actions and mechanisms of action. Trends Neurosci 1995; 18:130–6Rothwell, NJ Hopkins, SJ
Kim SY, Bae JC, Kim JY, Lee HL, Lee KM, Kim DS, Cho HJ: Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport 2002; 13:2483–6Kim, SY Bae, JC Kim, JY Lee, HL Lee, KM Kim, DS Cho, HJ
Nishikori T, Irie K, Suganuma T, Ozaki M, Yoshioka T: Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation. Eur J Pharmacol 2002; 451:327–33Nishikori, T Irie, K Suganuma, T Ozaki, M Yoshioka, T
Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF: Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 1997; 71:225–35Watkins, LR Martin, D Ulrich, P Tracey, KJ Maier, SF
Watkins LR, Maier SF, Goehler LE: Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995; 63:289–302Watkins, LR Maier, SF Goehler, LE
Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S: Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha. Br J Pharmacol 1997; 121:417–24Woolf, CJ Allchorne, A Safieh-Garabedian, B Poole, S
Raghavendra V, Tanga FY, DeLeo JA: Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004; 20:467–73Raghavendra, V Tanga, FY DeLeo, JA
Tsuruoka M, Arai YC, Nomura H, Matsutani K, Willis WD: Unilateral hindpaw inflammation induces bilateral activation of the locus coeruleus and the nucleus subcoeruleus in the rat. Brain Res Bull 2003; 61:117–23Tsuruoka, M Arai, YC Nomura, H Matsutani, K Willis, WD
Jin SX, Zhuang ZY, Woolf CJ, Ji RR: p38 Mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003; 23:4017–22Jin, SX Zhuang, ZY Woolf, CJ Ji, RR
Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279:1453–61Badger, AM Bradbeer, JN Votta, B Lee, JC Adams, JL Griswold, DE
Ji RR, Baba H, Brenner GJ, Woolf CJ: Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 1999; 2:1114–9Ji, RR Baba, H Brenner, GJ Woolf, CJ
Ji RR, Befort K, Brenner GJ, Woolf CJ: ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 2002; 22:478–85Ji, RR Befort, K Brenner, GJ Woolf, CJ
Aley KO, Martin A, McMahon T, Mok J, Levine JD, Messing RO: Nociceptor sensitization by extracellular signal-regulated kinases. J Neurosci 2001; 21:6933–9Aley, KO Martin, A McMahon, T Mok, J Levine, JD Messing, RO
Dai Y, Iwata K, Fukuoka T, Kondo E, Tokunaga A, Yamanaka H, Tachibana T, Liu Y, Noguchi K: Phosphorylation of extracellular signal-regulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. J Neurosci 2002; 22:7737–45Dai, Y Iwata, K Fukuoka, T Kondo, E Tokunaga, A Yamanaka, H Tachibana, T Liu, Y Noguchi, K
Obata K, Yamanaka H, Dai Y, Tachibana T, Fukuoka T, Tokunaga A, Yoshikawa H, Noguchi K: Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. J Neurosci 2003; 23:4117–26Obata, K Yamanaka, H Dai, Y Tachibana, T Fukuoka, T Tokunaga, A Yoshikawa, H Noguchi, K
Fletcher D, Kayser V, Guilbaud G: Influence of timing of administration on the analgesic effect of bupivacaine infiltration in carrageenin-injected rats. Anesthesiology 1996; 84:1129–1137Fletcher, D Kayser, V Guilbaud, G
Gentili ME, Mazoit JX, Samii KK, Fletcher D: The effect of a sciatic nerve block on the development of inflammation in carrageenan injected rats. Anesth Analg 1999; 89:979–84Gentili, ME Mazoit, JX Samii, KK Fletcher, D
Bileviciute-Ljungar I, Lundeberg T: Contralateral but not systemic administration of bupivacaine reduces acute inflammation in the rat hindpaw. Somatosens Mot Res 2000; 17:285–93Bileviciute-Ljungar, I Lundeberg, T
Beloeil H, Asehnoune K, Moine P, Benhamou D, Mazoit JX: Bupivacaine action on the carrageenan-induced inflammatory response in mice: Cytokine production by leukocytes after ex-vivo stimulation. Anesth Analg 2005; 100:1081–6Beloeil, H Asehnoune, K Moine, P Benhamou, D Mazoit, JX
Colburn RW, DeLeo JA, Rickman AJ, Yeager MP, Kwon P, Hickey WF: Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmunol 1997; 79:163–75Colburn, RW DeLeo, JA Rickman, AJ Yeager, MP Kwon, P Hickey, WF
Tan Z, Dohi S, Ohguchi K, Nakashima S, Nozawa Y: Local anesthetics inhibit muscarinic receptor-mediated activation of extracellular signal-regulated kinases in rat pheochromocytoma PC12 cells. Anesthesiology 1999; 91:1014–24Tan, Z Dohi, S Ohguchi, K Nakashima, S Nozawa, Y
Donaldson LF, McQueen DS, Seckl JR: Local anaesthesia prevents acute inflammatory changes in neuropeptide messenger RNA expression in rat dorsal root ganglia neurons. Neurosci Lett 1994; 175:111–3Donaldson, LF McQueen, DS Seckl, JR
Bileviciute-Ljungar I, Biella G, Bellomi P, Sotgiu ML: Contralateral treatment with lidocaine reduces spinal neuronal activity in mononeuropathic rats. Neurosci Lett 2001; 311:157–60Bileviciute-Ljungar, I Biella, G Bellomi, P Sotgiu, ML
Bileviciute-Ljungar I, Lundeberg T: Contralateral treatment with Xylocaine reduces nociceptive behaviour in mononeuropathic rats. Neuroreport 2000; 11:291–5Bileviciute-Ljungar, I Lundeberg, T
Fig. 1. Tumor necrosis factor-α content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
Fig. 1. Tumor necrosis factor-α content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
	*P  < 0.05. 
Fig. 1. Tumor necrosis factor-α content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
×
Fig. 2. Interleukin-1β content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
Fig. 2. Interleukin-1β content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
	*P  < 0.05. 
Fig. 2. Interleukin-1β content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
×
Fig. 3. p38 content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
Fig. 3. p38 content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
Fig. 3. p38 content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
×
Fig. 4. Phosphorylated p38 (p-p38) content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
Fig. 4. Phosphorylated p38 (p-p38) content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin. 
	*P  < 0.05. 
Fig. 4. Phosphorylated p38 (p-p38) content (pg/ml) at 15 h in the spinal cord (  A  ) and dorsal root ganglia (  B  ) after right paw carrageenan injection. Bupi = bupivacaine; carr = carrageenan; contra = contralateral; ipsi = ipsilateral; TTX = tetrodotoxin.  *P  < 0.05. 
×
Table 1. Summary of the Treatment Groups 
Image not available
Table 1. Summary of the Treatment Groups 
×